Amended Statement of Beneficial Ownership (3/a)
March 28 2022 - 5:31PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Belldegrun Arie |
2. Date of Event Requiring Statement (MM/DD/YYYY)
9/16/2021
|
3. Issuer Name and Ticker or Trading Symbol
Ginkgo Bioworks Holdings, Inc. [DNA]
|
(Last)
(First)
(Middle)
C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
BOSTON, MA 02210
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY) 9/20/2021
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Class A Common Stock | 18741 | D | |
Class A Common Stock | 500000 (1) | I | By Bellco Legacy LLC (2) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Warrants | 10/16/2021 | 9/16/2026 | Class A Common Stock | 3748 | $11.50 | D | |
Explanation of Responses: |
(1) | Reflects shares of Class A Common Stock acquired in a pro rata distribution in-kind, the acquisition of which was exempt pursuant to Rule 16a-9. |
(2) | Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Belldegrun Arie C/O GINKGO BIOWORKS HOLDINGS, INC. 27 DRYDOCK AVENUE BOSTON, MA 02210 | X |
|
|
|
Signatures
|
/s/ Karen Tepichin, Attorney-in-fact | | 3/28/2022 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Apr 2023 to Apr 2024